Product Spotlight: Liquid Urinalysis Control
Liquid Urinalysis Quality Control
The Randox Acusera Urinalysis Quality Control is designed primarily to ensure accurate test system performance however offer the laboratory additional benefits that will help them to meet regulatory requirements whilst also reducing costs and time.
Background
It is estimated that 1 in 2 people will be affected by a urological condition at some point in their lifetime. Conditions and diseases related to kidneys, bladder and prostate, among others, are commonplace and can be devastating for millions of men, women and children across the globe.
Urological conditions can be common, such as urinary tract infections, or they can be much more serious, for example, prostate or testicular cancer.
Urinalysis is used as a screening or diagnostic tool because it can detect kidney and metabolic disorders. Often, substances such as glucose or protein will appear in the urine before a patient is aware that they have a problem. In some conditions, urinalysis also provides an easy and economical test to track patient progress, for example, if you want to know if a condition is improving.
Key Benefits & Features
- Liquid ready-to-use
- 100% human urine
- Assayed ranges provided for 13 parameters
- Suitable for use in POC testing
- Stable to expiry date at 2°C – 8°C
- Open vial stability of 30 days at 2°C – 25°C (20 immersions for UC5033/5034)
Consolidation
As a leading provider of multi-analyte, third party controls, Randox helps busy laboratories significantly reduce the number of controls needed to cover their test menu. The Randox Liquid Urinalysis Control combines multiple analytes into a single control reduces cost, preparation time, and required storage space without sacrificing quality. Analytes at key decision levels will ensure test system performance across the clinical range. It can also be used in monitoring the performance of both automated and manual methods of urine test strip analysis.
Liquid Stable
Samples are conveniently supplied ready-to-use requiring no preparation as such they can save valuable laboratory time. The Acusera Liquid Urinalysis Control can be used for POCT as well as laboratory based testing.
True third party quality control
The Acusera Liquid Urinalysis Quality Control is a true third party control designed to provide an unbiased assessment of performance with a range of instruments and methods, helping your laboratory meet the ISO 15189 requirements.
“the use of third party control materials should be considered,
either instead of, or in addition to, any control materials
supplied by the reagent or instrument manufacturer”.
Analytes
- Albumin
- Bilirubin
- Blood
- Creatinine
- Glucose
- hCG
- Ketones
- Leukocytes
- Nitrate
- pH
- Protein
- Specific Gravity
- Urobilinogen
Complete QC solution
The combining of the Acusera Liquid Urinalysis Quality Control, RIQAS Urinalysis EQA programme, and our Acusera 24•7 software will provide a complete QC solution for laboratories of all sizes.
Download some of our related brochures below and broaden your understanding.
RIQAS Instrument Group Report
All RIQAS participants are entitled to register up to five separate instruments per programme at no extra cost.
Individual reports for each instrument are supplied as normal in addition to a complimentary instrument group report allowing the performance of each instrument to be uniquely compared and assessed easily.
RIQAS EQA Reports
The multi-instrument group report displays the %Deviation for the last 10 samples along with the RM%Dev across all registered laboratory instruments. The %Dev for each instrument is plotted on a user-friendly, colour coded chart for instant identification of poor performing instruments.
As an ISO requirement, the Multi-Instrument Report is an extremely useful and beneficial tool for laboratories – “Laboratories with two or more analysers for examinations, should have a defined mechanism for comparison of results across analysers” – ISO 15189:2012.
(Click to enlarge image)
RIQAS Inter-Laboratory Group Report
A unique group reporting facility is available allowing laboratory groups or chains to effectively monitor the performance of satellite sites.
All laboratories within a group will receive their RIQAS sample packs, analyse the samples, return results to RIQAS and receive their individual RIQAS reports as normal. In addition to this a separate group report will be sent to the group manager or supervisor allowing relative performance of all laboratories within the group to be assessed.
RIQAS EQA Reports
For each laboratory in the group, the interlaboratory group report displays the %Dev for the last 10 samples along with the RM%Dev. The %Dev for each laboratory is plotted on a user-friendly, colour coded chart for instant identification of poor performing labs.
(Click to enlarge image)
RIQAS End-of-Cycle Report
RIQAS End-of-Cycle reports are sent to all participants who receive the standard report. Therefore, participants who are enrolled in RIQAS Urinalysis, RIQAS Urine Toxicology and RIQAS Serology programmes will not receive an End-of-Cycle report.
The RIQAS End-of-Cycle report provides laboratories with a complete summary of their External Quality Assessment performance. Performance is also compared to that of the previous cycle providing an indication of progress and improvement over time. Data is presented in both written and graphical format allowing a visual assessment of overall performance.
The RIQAS End-of-Cycle report is split into 3 sub-sections. These sub-sections are designed to allow performance assessment at a glance.
RIQAS EQA Reports
RIQAS End-of-Cycle Report Features
The Parameter Cycle Summary section provides an overview of the results returned for each sample in the cycle. The text section summarises the laboratory’s result compared to the Mean for Comparison. Laboratory performance for the current cycle is also compared to that of the previous cycle. A variety of charts including Levey-Jennings, Target Score, % Deviation by sample and % Deviation by concentration are also presented allowing a visual assessment of laboratory performance over the cycle.
(Click to enlarge)
The text section provides a summary of the laboratory’s results and statistics including Mean for Comparison, SDPA, %CV, Uncertainty, SDI, Target Score and % Deviation. An additional table comparing performance for the current cycle to the previous cycle is also provided.
(Click to enlarge)
The laboratory’s performance is summarised in various charts including Levey-Jennings, Target Score, % Deviation by sample and % Deviation by Concentration.
(Click to enlarge)
The absolute SDI summary report compares current performance for all parameters to the previous cycle and indicates whether performance is better or worse. Performance is compared to other RIQAS participants in your country and worldwide.
(Click to enlarge)
A certificate of performance is provided listing all parameters, for which the laboratory achieved an acceptable level of performance (Average Absolute SDI <2). Although the End-of-Cycle Report is issued for all registered parameters, the certificate of performance will only be available for parameters where results for at least 50% of samples in the cycle have been returned.
(Click to enlarge)
RIQAS Standard Report
There are a variety of RIQAS reports designed to enable quick and easy identification of any trends or test system issues. The standard quantitative report is provided in a user-friendly, one page per parameter format allowing a visual, at-a-glance assessment of performance. The standard quantitative report is split into several easy to interpret subsections each designed to save valuable laboratory time.
You can explore each of the report sections using the table below. Don’t forget, to enlarge the image, simply click on it.
RIQAS EQA Reports
RIQAS Reports Features
Performance data is presented in a simple one page format for each analyte. Each one page report comprises seven sub-reports providing a statistical and graphical representation of laboratory performance.
(Click to enlarge)
The text section provides a statistical breakdown of results by all methods, your method and instrument group. The Mean, CV% and Uncertainty or Measurement is presented for each comparison group.
Your laboratory’s result is compared to the Mean for Comparison (usually the instrument group Mean). Also included are the RIQAS performance indicators; SDI, Target Score and %Deviation.
Acceptable performance criteria:
- SDI <2
- Target Score >50
- %Deviation
The defined acceptable limits default to the RIQAS TDPA values but may be based on CLIA, biological variation or country specific limits.
Performance goals based on Biological Variation are also stated within the text section for information purposes.
(Click to enlarge)
The histogram chart provides an overview of how your laboratory’s result compares to the all method group, your method group and your instrument group. Your result is represented by a black triangle; the closer to the centre the better.
The chart is intended to provide a quick visualisation of performance compared to other method groups and can be used to identify any potential bias.
(Click to enlarge)
The Levey-Jennings chart plots the last 20 SDI’s and is extremely useful for monitoring EQA performance over time, allowing quick and easy identification of any trends or bias. The chart is colour coded making interpretation simple and easy; results that fall in the white area are excellent and those in the red area unacceptable.
(Click to enlarge)
The Target Score (TS) chart is a unique chart which displays your laboratory’s last 20 target scores delivering an instant, visual indication of performance. The TS chart is conveniently colour coded for even easier performance assessment, a TS >50 is acceptable. The TS is a numerical index relating your %Deviation from the mean to a Target Deviation for Performance Assessment (TDPA).
(Click to enlarge)
The %Deviation by sample chart displays the %Deviation for the last 20 EQA samples enabling identification of trends and shifts in performance. Similar to the other charts on the RIQAS report, the %Deviation by sample chart is shaded to indicate the limit of acceptable performance. A black dot within the white section of the chart will represent results with a %Deviation within your acceptable limits of performance; a black dot within the red section of the chart will represent results with a %Deviation outside your acceptable limits of performance. %Deviations are not influenced by the performance of your peers, as seen with the standard deviation index (SDI) and therefore is a better indicator of individual performance.
(Click to enlarge)
The %Deviation by concentration chart enables easy detection of possible concentration related biases. Unlike the other charts provided on the report, the %Deviation by concentration chart displays the concentration range of the previous 20 samples along the bottom of the chart.
Using this scale along with the percentage deviation, you are provided with a rapid assessment of your %Deviation in relation to the concentration of the:
• Current sample (represented by a square)
• Your 19 previous results (represented by circles)
This chart provides an easy interpretation of potential positive or negative biases at high or low concentrations, or whether a particular sample is a random outlier.
(Click to enlarge)
The Multi Method Stat Section provides you with an easy way of assessing the performance of the other methods used to analyse the parameter. This is useful when your laboratory plans to change the analytical method used for the parameter.
(Click to enlarge)
Located at the back of the standard quantitative report, our quick reference summary page details the performance for each registered parameter in the programme.
Within the performance column, RIQAS provides an effortless method of assessing the performance of each parameter within the sample distribution. When a red triangle appears next to the parameter, this indicates that all performance indicators (SDI, TS and %DEV) have exceeded the performance criteria.
The performance indicator limits for each parameter are exceeded when your result produces:
• An SDI greater than +/- 2 standard deviations.
• A Target Score less than 50 (only when Target Scoring is available)
• A %Deviation greater than your set acceptable limits of performance.
(Click to enlarge)
A summary CSV file is available on request to all participating laboratories. The report provides a summary of all statistics, acceptable limits and performance indicators as a .csv file for each sample in the cycle.
A retrospective statistics summary is also available, four weeks after the final submission date for parameters where a result was not submitted on time.
RIQAS Parameters List
RIQAS is the largest international External Quality Assessment (EQA)/ Proficiency Testing (PT) scheme, there are currently more than 55,000 participants in 134 countries. World renowned for reducing the number of individual programmes required by even the most demanding laboratories, RIQAS covers 360 parameters across 36 flexible multi-parameter programmes. Effective consolidation in this way will not only deliver real cost savings but free up storage space and ultimately reduce the time spent preparing multiple samples at each survey.
RIQAS Parameter List
1-25-(OH)₂-Vitamin D
17-OH-Progesterone
25-OH-Vitamin D
5-HIAA
α-1-Acid Glycoprotein
α-1-Antitryspin
α-2-Macroglobulin
ACE (Angiotensin Converting Enzyme)
Acid Phosphatase (Prostatic)
Acid Phosphatase (Total)
ACR
ACTH
AFP
Albumin
Aldosterone
Alkaline Phosphatase
ALT
ALT (ALAT)
Amikacin
Ammonia
Amylase (Pancreatic)
Amylase (Total)
Androstenedione
Anti Streptolysin O (ASO)
Anti-CMV
Anti-CMV IgG
Anti-CMV IgM
Anti-EBNA IgG
Anti-EBV VCA IgG
Anti-EBV VCA IgM
Anti-HAV IGM*
Anti-HAV (Total)*
Anti-HBc
Anti-HBc IgM*
Anti-HBe (Total)*
Anti-HBs (Total)*
Anti-HCV
Anti-HIV-1
Anti-HIV-1 & 2 Combined
Anti-HIV-2
Anti-HSV- 1 & 2 IgG Combined
Anti-HSV- 1 & 2 IgM Combined
Anti-HSV1 IgG
Anti-HSV1 IgM
Anti-HSV2 IgG
Anti-HSV2 IgM
Anti-HTLV-1 & 2 Combined
Anti-HTLV-I
Anti-HTLV-II
Anti-Measles IgG*
Antimicrobial Susceptibility Testing
Anti-Müllerian Hormone (AMH)
Anti-Mumps IgG*
Anti-Rubella IgG
Anti-Rubella IgM
Anti-SARS-COV2 IgG
Anti-SARS-COV2 IgM
Anti-SARS-COV2 Total
Anti-TG
Antithrombin III
Anti-Toxoplasma IgG
Anti-Toxoplasma IgM
Anti-TPO
Anti-TSH Receptor (TRAb)
Anti-VZV IgG*
Apolipoprotein AI
Apolipoprotein B
aPTT
AST
AST (ASAT)
β-2-Microglobulin
Benzoylecgonine
Bicarbonate
Bile Acids
Bilirubin (Direct)
Bilirubin (Total)
Blood
BNP
Buprenorphine
CA15-3
CA19-9
CA125
Caffeine
Calcitonin
Calcium
Calcium, Adjusted
Calcium (Ionised)
Cannabinoids (THC)
Carbamazepine
Carboxyhaemoglobin (COHb / HbCO)
CEA
Ceruloplasmin
Chloride
Cholesterol (Total)
Cholinesterase
Ciclosporin
CK, Total
CK-MB (Activity)
CK-MB (Mass)
CK NAC
CO2, Total
Complement C₃
Complement C₄
Conductivity
Copper
Cortisol
Cotinine
C-Peptide
C-Reactive Protein (CRP)
Creatinine
CYFRA 21-1 (Cytokeratin 19)
D-3-Hydroxybutyrate
d-Amphetamine
D-Dimer*
Deoxyhaemoglobin (HHb)
DHEA Unconjugated
DHEA-Sulphate
Digoxin
d-Methamphetamine
Dopamine
EDDP
Epinephrine
ESR
Estriol Total
Ethanol
Ethosuximide
Everolimus
Factor II
Factor IX
Factor V
Factor VII
Factor VIII
Factor X
Factor XI
Factor XII
Ferritin
Fibrinogen
Folate
Free Morphine
free β-hCG
Fructosamine
FSH
γ-GT
Galactose
Gastrin
Gentamicin
Growth Hormone (GH)
GLDH
Glucose
Haematocrit (HCT)
Haemoglobin (Hb)
Total Haemoglobin (tHb)
Haemolysis
Haptoglobin
HbA1c
HBsAG
HBDH
hCG
HDL-Cholesterol
Homocysteine
hsCRP
Icteric
IgA
IgE
IGF-1
IgG
IgM
Inhibin A
Insulin
Interferon gamma (INF-Y)*
Interleukin – 1 alpha (IL-1α)*
Interleukin – 1 beta (IL-1β)*
Interleukin – 10 (IL-10)*
Interleukin – 2 (IL-2)*
Interleukin – 4 (IL-4)*
Interleukin – 6 (IL-6)
Interleukin – 8 (IL-8)*
Iron
Kappa Light Chain (Free)
Kappa Light Chain (Total)
Ketones
Lactate
Lambda Light Chain (Free)
Lambda Light Chain (Total)
LD (LDH)
LDL-Cholesterol
Lead
Leucocytes
Lipase
Lipoprotein (a)
Lithium
Lorazepam
LSD
Luteinising Hormone (LH)
Magnesium
MDMA
Mean Cell Haemoglobin (MCH)
Mean Cell Haemoglobin Concentration (MCHC)
Mean Cell Volume (MCV)
Mean Platelet Volume (MPV)
Metanephrine
Methadone
Methaemoglobin (MetHb)
Methotrexate
Monocyte Chemoattractant Protein -1 (MCP-1)*
Myoglobin
NEFA
Nitrite
Non-HDL Cholesterol
Norepinephrine
Normetanephrine
Norpropoxyphene
Nortriptyline
NT proBNP
Oestradiol
Osmolality
Osteocalcin
Oxalate
Oxazepam
Oxygen Content (O2CT)
Oxygen Saturation (sO2 / Vol O2)
Oxyhaemoglobin (O2Hb / HbO2)
P24*
PAPP-A
Paracetamol (Acetaminophen)
pCO₂
pH
Phencyclidine
Phenobarbital
Phenytoin
Phosphate (Inorganic)
Plasma Renin Activity
Plasminogen
Plateletcrit (PCT)
Platelets (PLT)
pO₂
Potassium
Prealbumin (Transthyretin)
Primidone
Procalcitonin
Progesterone
Prolactin
Protein (Total)
Protein C
Protein S
PSA (Free)
PSA (Total)
PT (Including INR)
PTH
Red Blood Bell Count (RBC)
Red Cell Distribution Width (RDW)
Renin (Direct Concentration)
Retinol Binding Protein
Rheumatoid Factor
Salicylic Acid
Secobarbital
SHBG
Sirolimus
Sodium
Specific Gravity
Syphilis
T₃ (Free)
T₃ (Total)
T₄ (Free)
T₄ (Total)
Tacrolimus
Testosterone (Free)*
Testosterone (Total)
Theophylline
Thyroglobulin
TIBC
Tobramycin
Total hCG
Transferrin
Triglycerides
Troponin I
Troponin T
TSH
TT
Tumor Necrosis Factor alpha (TNF-a)*
UIBC
Unconjugated Oestriol
Urea
Uric Acid
Urobilinogen
Valproic Acid
Vancomycin
Vascular Endothelial Growth Factor (VEGF)*
Vitamin B₁₂
VMA
Total White Blood Cell Count (WBC)
Zinc
Acusera Internal Quality Control Analyte List
Quality Control is our passion; we believe in producing high quality material that can help streamline procedures, whilst saving time and money for laboratories of all sizes and budgets. With an extensive product offering comprising third party controls and calibrators, interlaboratory data management, external quality assessment, and calibration verification, you can count on Randox to deliver trustworthy results time and time again. Just ask one of our 60,000 users worldwide.
Our Acusera Internal Quality Control A – Z analyte list highlights how comprehensive our Acusera product portfolio is. Search through the list to see if we have the analyte you require.
Acusera Parameter List
5-HIAA
17-OH-progesterone
17β Clostebol
1-25-(OH₂)-Vitamin D
25-OH-Vitamin D
α-1-Acid Glycoprotein
α-1-Antitrypsin
α-1-Globulin (Electrophoresis)
α-2-Globulin (Electrophoresis)
α-2-Macroglobulin
α-Fetoprotein (AFP)
α-HBDH
ACE (Angiotensin Converting Enzyme)
Acetaminophen
Acid Phosphatase (Non-Prostatic)
Acid Phosphatase (Prostatic)
Acid Phosphatase (Total)
ACTH
Activated Partial Thromboplastin Time (APTT)
AHD
Albumin
Albumin (Electrophoresis)
Aldolase
Aldosterone
Alkaline Phosphatase (ALP)
ALT (GPT)
AMH
Amikacin
Ammonia
AMOZ
Amylase
Amylase (Pancreatic)
Androstenedione
Anti-HAV
Anti-HBc
Anti-HBe
Anti-HBs
Anti-HCV
Anti-HIV 1 / 2
Anti-HTLV 1 / 2
Anti-SARS-CoV-2
Anti-SARS-CoV-2 Spike
Anti-Streptolysin (ASO)
Anti-Thyroglobulin (Anti-TG)
Anti-Thyroperoxidase (Anti-TPO)
Anti-Thrombin III (AT III)
AOZ
Apolipoprotein A-I
Apolipoprotein A-II
Apolipoprotein B
Apolipoprotein C-II
Apolipoprotein C-III
Apolipoprotein E
AST (GOT)
β-Globulin (Electrophoresis)
β-2-Microglobulin
BASO-X
BASO-Y
Basophils (BASO)
Basophils % (% BASO)
Bicarbonate
Bile Acids
Bilirubin (Direct)
Bilirubin (Total)
Blood
Bone Alkaline Phosphatase (B-ALP)
Borrelia burgdorferi IgG
Borrelia burgdorferi IgM
Brain Natriuretic Peptide (BNP)
C-Peptide
C-Telopeptide
CA 15-3
CA 19-9
CA 72-4
CA 125
Caffeine
Calcitonin
Calcium
Carbamazepine
CEA
Ceftiofur
Ceruloplasmin
Chloramphenicol
Chloride
Cholesterol (HDL)
Cholesterol (LDL)
Cholesterol (Total)
Cholinesterase
CK-MB
CK (Total)
Complement C3
Complement C4
Copper
Cortisol
CRP
Creatinine
Cyclosporine
Cytomegalovirus (CMV) IgG
Cytomegalovirus (CMV) IgM
CYFRA 21
Cystatin C
D-3-Hydroxybutyrate
D-dimer
Deoxypyridinoline
DHEA-Sulphate
DIFF-X
DIFF-Y
Digoxin
Dopamine
E-Selectin (E-SEL)
Eosinophils (EOS)
% Eosinophils (% EOS)
Epidermal Growth Factor (EGF)
Epinephrine
Epstein Barr Virus (EBV) EBNA IgG
Epstein Barr Virus (EBV) IgM
Epstein Barr Virus (EBV) VCA IgG
Estriol
Ethanol
Ethinylestradiol
Ethosuximide
Factor II
Factor V
Factor VII
Factor VIII
Factor IX
Factor X
Factor XI
Factor XII
Ferritin
Fibrinogen
Folate
Fructosamine
FSC-X
FSH
G-6-PDH
γ-Globulin (Electrophoresis)
γGT
Gastrin
Gentamicin
Gestagens (Generic)
GLDH
Glucose
Glutamate
Glutathione Peroxidase (Ransel)
Glutathione Reductase
Glycerol
GM-CSF
Growth Hormone (GH)
Haematocrit (HCT)
Haemoglobin (HGB)
Haemoglobin (Total)
Haemolysis (H)
Haemopioetic Progenitor Cell (HPC)
Haptoglobin
HAV IgM
HbA1c
HBc IgM
HBeAg
HBsAg
hCG
Free β-hCG
Total β-hCG
HDL-3
Helicobacter pylori IgG
Herpes Simplex Virus 1 (HSV-1) IgG
Herpes Simplex Virus 1 (HSV-1) IgM
Herpes Simplex Virus 2 (HSV-2) IgG
Herpes Simplex Virus 2 (HSV-2) IgM
HIV-1 P24Ag
Homocysteine
Icterus (I)
IMIDC
IMIRF
Immature Granulocytes (IG)
% Immature Granulocytes (% IG)
Immature Myeloid Information (IMI)
Immature Platelet Fraction (IPF)
Immunoglobulin A (IgA)
High Sensitivity Immunoglobulin A (hsIgA)
Immunoglobulin E (IgE)
Immunoglobulin G (IgG)
High Sensitivity Immunoglobulin G (hsIgG)
Immunoglobulin M (IgM)
High Sensitivity Immunoglobulin M (hsIgM)
Inhibin A
Insulin
Intercellular Adhesion Molecule-I (ICAM-I)
Interferon-γ (IFN-γ)
Interleukin-Ia (IL-la)
Interleukin-1β (IL-1β)
Interleukin-2 (IL-2)
Interleukin-4 (IL-4)
Interleukin-5 (IL-5)
Interleukin-6 (IL-6)
Interleukin-8 (IL-8)
Interleukin-10 (IL-10)
Interleukin-15 (IL-15)
Iron
Iron (TIBC)
Iron (UIBC)
Kappa Light Chain
Ketones
L-Selectin (L-SEL)
Lactate
Lactate Dehydrogenase (LDH)
Lambda Light Chain
Lambda Light Chain (Free)
LAP
Leptin
Leukocytes
Lipase
Lipemia (L)
Lipoprotein (a)
Lithium
Luteinising Hormone (LH)
Lymphocytes (LYMPH)
% Lymphocytes (% LYMPH)
Magnesium
Matrix Metalloproteinase-9 (MMP-9)
Measles IgG
Mean Corpuscular Haemoglobin (MCH)
Mean Corpuscular Haemoglobin Concentration (MCHC)
Mean Corpuscular Volume (MCV)
Mean Platelet Volume (MPV)
Metanephrine
Methandriol
Methotrexate
Methyltestosterone
Microalbumin
Macrophage Inflammatory Protein-1a (MIP-1a)
Monocytes (MONO)
Monocytes % (% MONO)
Monocyte Chemoattractant Protein-1 (MCP-1)
Mumps IgG
Myoglobin
Methyltestosterone
MDMA
Microalbumin
Macrophage Inflammatory Protein-1α (MIP-1α)
Monocytes (MONO)
Monocytes % (% MONO)
Monocyte Chemoattractant Protein-1 (MCP-1)
Morphine (Opiates)
Myoglobin
N-MID Osteocalcin (OC)
N-Telopeptide
NEFA
Neuron-Specific Enolase (NSE)
Neutrophils (NEUT)
Neutrophils % (% NEUT)
Neutrophil Gelatinase-associated Lipocalin (NGAL)
Nitrite
Norepinephrine
Normetanephrine
NT-proBNP
Nucleated Red Blood Cells (NRBC)
Nucleated Red Blood Cells % (% NRBC)
Nucleated Red Blood Cells X (NRBC-X)
Nucleated Red Blood Cells Y (NRBC-Y)
Oestradiol
Osmolality
Osteocalcin
Oxalate
Oxyhaemoglobin
P-Selectin (P-SEL)
Paracetamol
PAPP-A
pCO₂
pH
Phencyclidine
Phenobarbital
Phenylpiperazines
Phenytoin
Phosphate (Inorganic)
Plasminogen
Plasminogen Activator Inhibitor
Platelet Distribution Width (PDW)
Platelet Large Cell Ratio (P-LCR)
Plateletcrit (PCT)
Platelet (PLT)
Platelet Optical Count (PLT-O)
pO₂
Potassium
Prealbumin
Primidone
Procalcitonin
Procollagen Type 1 N-Terminal Propeptide (P1NP)
Progesterone
Prolactin
Protein C
Protein S
Protein (Total)
Prothrombin Time (PT)
Pyridinium Crosslinks
Pyridinoline
PSA (Total)
PSA (Free)
PTH (Parathyroid Hormone)
PTH (Intact)
Quinolones
Red Blood Cell Y (RBC-Y)
Red Blood Cell Distribution Width CV (RDW-CV)
Red Blood Cell Distribution Width SD (RDW-SD)
Renin
Resistin
Retinol Binding Protein (RBP)
Rheumatoid Factor (RF)
Rubella IgG
Rubella IgM
Salicylate
Semicarbazine (SEM)
Sex Hormone Binding Globulin (SHBG)
sLDL
Sodium
Soluble IL-2 Receptor α (sIL-2Rα)
Soluble IL-6 Receptor (sIL-6R)
Soluble Transferrin Receptor (sTfR)
Soluble Tumour Necrosis Factor Receptor 1 (sTNFR I)
Soluble Tumour Necrosis Factor Receptor 11 (sTNFR I1)
Specific Gravity
Streptomycin
Superoxide Dismutase (Ransod)
T Uptake
T3 (Free)
T4 (Free)
T3 (Total)
T4 (Total)
Testosterone
Testosterone (Free)
Tetracyclines (Generic)
Theophylline
Thiamphenicol
Thrombin Time (TT)
Thyroglobulin
Tobramycin
Total Antioxidant Status (TAS)
Toxoplasma gondii IgG
Toxoplasma gondii IgM
Transferrin
Treponema pallidum (Syphilis) IgG
Triglycerides
Trimethoprim
Troponin I
Troponin T
TSH
Tumour Necrosis Factor α (TNFα)
Tylosin
Unconjugated Estriol
Urea
Uric Acid (Urate)
Urobilinogen
Valproic acid
Vancomycin
Vanillylmandelic Acid (VMA)
Varicella Zoster Virus (VZV) IgG
Vascular Cell Adhesion Molecule-1 (VCAM-1)
Vascular Endothelial Growth Factor (VEGF)
Vitamin B₁₂
White Blood Cells (WBC)
White Blood Cells Differential (WBC-D)
Zinc
Product Spotlight: Maternal Screening
Maternal Screening Control
Background
A maternal serum screening test (MSS) is a blood test offered to pregnant women that helps determine the risk of Down’s syndrome and other chromosomal conditions, further testing can be offered if the patient is found to be high risk. It can be performed at 10 weeks (combined first trimester screening test), and 14-20 weeks (second trimester maternal serum screening test).
MSS is generally offered to all pregnant women, but the decision to have the test is a personal decision.
Quality Control is an important part of any diagnostic test but is of particular importance in screening methods, when a disorder must be detected without the presence of symptoms. In such screening methods, errors can present as false negative or false positive results both of which can have devastating consequences. In the case of maternal screening a false positive result could mean additional and often invasive procedures which can carry risk of harm to the unborn child. The accuracy and reliability of the laboratory test results are extremely important in minimising both false positive and false negative results.
Product Overview
The Randox Acusera Maternal Screening quality control is the only commercially available control which covers all six analytes used during first and second trimester screening of Down’s syndrome and Spina Bifida.
Instrument specific target values and ranges are provided for AFP, Inhibin A, PAPP-A, β hCG, Total hCG and Unconjugated Estriol. The inclusion of PAPP-A and Inhibin A eliminates the need to purchase additional controls at extra expense.
Key Benefits & Features
- Lyophilised for enhanced stability
- 100% human serum
- Assayed target values provided for 6 parameters
- Suitable for double, triple and quad screens
- Unconjugated Estriol present at clinically significant levels
- Reconstituted stability of 7 days at 2°C – 8°C
- Stable to expiry date at 2°C – 8°C
Consolidation
As a leading provider of multi-analyte, third party controls, Randox helps busy laboratories significantly reduce the number of controls needed to cover their test menu. Combining multiple analytes into a single control reduces cost, preparation time, and required storage space without sacrificing quality.
Analytes at key decision levels will not only ensure test system performance across the clinical range but will further aid consolidation and maximise laboratory efficiency by eliminating the need to purchase additional and often expensive low or high level controls.
First and second trimester
As the only control on the market to cover all first and second trimester analytes, you can be sure that your lab is covering all bases.
True third party control
The Acusera Maternal Screening Control is a true third party control designed to provide an unbiased assessment of performance with a range of instruments and methods, helping your laboratory meet the ISO 15189 requirements.
“the use of third party control materials should be considered,
either instead of, or in addition to, any control materials
supplied by the reagent or instrument manufacturer”.
Analytes
- AFP
- PAPP-A
- Free Beta hCG
- Total hCG
- Inhibin A
- Unconjugated Oestriol
Related Products:
Download some of our related brochures below and broaden your understanding.
Product Spotlight: Liquid CSF Control
Liquid CSF Control
Cerebral Spinal Fluid (CSF) is produced by the body to protect, provide nutrients, and remove waste from the Central Nervous System (CNS). The CNS consists of the brain, spinal cord, and a complex neuron network. It is responsible for sending information to and receiving information from all parts of the body, co-ordinating organ function and responding to changes in the immediate external environment.
When testing CSF, it is removed from the subarachnoid space via lumbar puncture or spinal tap. The analysis of CSF includes tests such as; clinical chemistry, haematology, immunology and microbiology. These are used to diagnose serious bacterial, fungal, and viral infections, such as meningitis, a cerebral bleed, cancer involving the CNS and inflammatory conditions of the CNS.
Product Overview
Providing a true third party solution for the measurement of Cerebrospinal Fluid (CSF), the Acusera Liquid CSF Control is designed to deliver an unbiased, independent assessment of analytical performance helping to ensure accurate and reliable patient testing of 14 analytes.
Key Features & Benefits
- Liquid ready-to-use samples requiring no preparation
- Human based material
- Assayed target values available
- True third party control providing unbiased performance assessment
- Shelf life of 2 years from date of manufacture
- Open vial stability of 30 days at 2ºC to 8ºC
Unrivalled Stability
Our Liquid CSF Control boasts a remarkable 30-day open vial stability reducing waste, while remaining easy and convenient to use.
A True Third Party Control
The Acusera CSF Control is a true third party control designed to provide an unbiased assessment of performance with a range of instruments and methods, helping your laboratory meet the ISO 15189 requirements.
“the use of third party control materials should be considered,
either instead of, or in addition to, any control materials
supplied by the reagent or instrument manufacturer”.
Analytes
- Albumin (electrophoresis)
- Alpha – 1- globulin (electrophoresis)
- Alpha – 2- globulin (electrophoresis)
- Beta- globulin (electrophoresis)
- Chloride
- Gamma – globulin (electrophoresis)
- Glucose
- hsIgA
- hsIgG
- hsIgM
- Lactate
- Microalbumin
- Protein (Total)
- Sodium
Download some of our related brochures below and broaden your understanding.
RIQAS – Randox International Quality Assessment Scheme
The World’s Largest External Quality Assessment Scheme
Uniquely connecting you with 45,000 laboratory participants across 32 flexible yet comprehensive programmes, RIQAS is the world’s largest external quality assessment (EQA) scheme. Access to maximised peer groups ensures availability of comparison data for a wide range of instruments and methods, ultimately increasing confidence in test system reliability. The added benefit of frequent analysis, user-friendly reports, multi-instrument reports and consolidated programmes makes a cost-effective, high quality EQA solution for any laboratory.
Benefits of RIQAS
Consolidation
Comprised of over 360 parameters in 32 comprehensive programmes, RIQAS streamlines EQA by significantly reducing the number of individual programmes required.
User-friendly reports
RIQAS presents reports in a simple one page per parameter format for at-a-glance performance assessment, including Levey-Jennings charts, Histograms, % Deviation charts, and more; providing a visual representation of laboratory performance, all within 24-72 hours of the submission deadline.
Frequency
Frequent analysis coupled with our rapid report turnaround will allow labs to pinpoint when an error occurred and implement any corrective actions necessary.
Flexibility
With 32 flexible EQA programmes available, RIQAS has something to suit every lab. Reduced parameter and report options ensures suitability for laboratories of every size and budget.
The ability to register up to 5 instruments per programme at no extra cost will ultimately save money facilitating comparative performance assessment.
Accreditation
Being part of a reputable External Quality Assessment scheme like RIQAS is highly encouraged by international and national regulatory bodies and will help your laboratory meet ISO 15189:2012 accreditation requirements:
“the laboratory shall participate in inter-laboratory comparisons such as those organised by external quality assessment schemes…”, “EQA should, as far as possible, cover the entire range of tests, and the entire examination process, from sample reception, preparation and analysis to interpretation and reporting.”
RIQAS systems and procedures are accredited to ISO 17043:2010 ‘Conformity Assessment – General Requirements for Proficiency Testing’ ensuring a high quality programme that is fit for purpose and will assist laboratories in meeting and maintaining ISO 15189:2012 standards.
In addition to ISO 17043:2010, RIQAS is recognised by the UK National Quality Assurance Advisory Panel (NQAAP) for Clinical Pathology and the Joint Working Group on Quality Assurance (JWG QA).
Learn More
To learn more or to get signed up, fill in the contact form below.
